Real‐world experience with Curcumin–QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study

Author:

Yanai Henit12ORCID,Salomon Nir3,Lahat Adi23ORCID,Ungar Bella23,Eliakim Rami23,Kriger‐Sharabi Ofra4,Reiss‐Mintz Hilla5,Koslowsky Benjamin67,Shitrit Ariella Bar‐Gil67,Tamir‐Degabli Natalie28,Dotan Iris12,Zittan Eran910ORCID,Maharshak Nitsan211,Hirsch Ayal211,Ben‐Horin Shomron23,Kopylov Uri23ORCID

Affiliation:

1. Division of Gastroenterology, Rabin Medical Center Petah Tikva Israel

2. Sackler School of Medicine Tel‐Aviv University Tel‐Aviv Israel

3. Department of Gastroenterology Sheba Medical Center Ramat Gan Israel

4. Department of Gastroenterology Assuta Medical Center Ashdod Israel

5. Department of Gastroenterology Mayanei HaYeshua Medical Center Bnei Brak Israel

6. Digestive Diseases Institute, Shaare Zedek Medical Center Jerusalem Israel

7. Faculty of Medicine Hebrew University of Jerusalem Jerusalem Israel

8. Department of Internal Medicine E Tel Aviv Sourasky Medical Center Tel‐Aviv Israel

9. Department of Gastroenterology and Liver Diseases, Emek Medical Center Afula Israel

10. The Rappaport Faculty of Medicine Technion‐Israel Institute of Technology Haifa Israel

11. Department of Gastroenterology Tel Aviv Medical Center Tel‐Aviv Israel

Abstract

SummaryBackgroundCurcumin and QingDai (QD, Indigo) have been shown to be effective for treating active ulcerative colitis (UC).AimTo evaluate the real‐world experience with the Curcumin–QingDai (CurQD) herbal combination to induce remission in active UC.MethodsA retrospec‑tive multicentre adult cohort study from five tertiary academic centres (2018–2022). Active UC was defined as a Simple Clinical Colitis Activity Index (SCCAI) ≥ 3. Patients were induced by CurQD. The primary outcome was clinical remission at weeks 8–12, defined as SCCAI ≤2 and a decrease ≥3 points from baseline. Secondary outcomes were clinical response (SCCAI decrease ≥3 points), corticosteroid‐free remission, faecal calprotectin (FC) response (reduction ≥50%), FC normalisation (FC ≤100 μg/g for patients with FC ≥300 μg/g at baseline), and safety. All outcomes were analysed for patients who were maintaining stable treatment.ResultsEighty‐eight patients were included; 50% were biologics/small molecules experienced, and 36.5% received ≥2 biologics/small molecules. Clinical remission was achieved in 41 (46.5%), and clinical response in 53 (60.2%). Median SCCAI decreased from 7 (IQR:5–9) to 2 (IQR:1–3); p < 0.0001. Of the 26 patients on corticosteroids at baseline, seven achieved corticosteroid‐free remission. Among 43 biologics/small molecules experienced patients, clinical remission was achieved in 39.5% and clinical response in 58.1%. FC normalisation and response were achieved in 17/29 and 27/33, respectively. Median FC decreased from 1000 μg/g (IQR:392–2772) at baseline to 75 μg/g (IQR:12–136) at the end of inductions (n = 30 patients with paired samples); p < 0.0001. No overt safety signals emerged.ConclusionIn this real‐world cohort, CurQD effectively induced clinical and biomarker remission in patients with active UC, including patients who were biologics/small molecules experienced.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3